JAK inhibitors for the treatment of palmoplantar pustulosis: a narrative review.

ABSTRACT:

Background

Palmoplantar pustulosis (PPP) is a chronic, relapsing skin condition characterized by sterile, pruritic pustules on erythematous, thickened skin of the palms and soles. It often causes painful fissures, leading to functional impairment and reduced quality of life. Due to its limited response to conventional therapies and biologic therapies, PPP remains a therapeutic challenge. Recent findings implicate both T helper 17 (T_H17)-mediated and T_H2-mediated inflammation, prompting interest in broader immunomodulatory treatments such as Janus kinase (JAK) inhibitors.

Methods

This narrative review evaluates current evidence on the efficacy and safety of JAK inhibitors in the treatment of PPP. Published studies involving tofacitinib, upadacitinib and

SUBMITTER: Henriques Dos Santos B 

PROVIDER: S-EPMC12582560 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature